常染色体显性多囊肾病临床试验设计的演变
本文综述了常染色体显性多囊肾病(ADPKD)临床试验设计的演变,指出因疾病进展缓慢,传统以肾功能终点(如eGFR变化或肾衰竭时间)为主的设计耗时耗资巨大;CRISP等研究验证了总肾体积(TKV)作为预后生物标志物和合理可能替代终点的价值,HALT-PKD和TEMPO 3:4等试验进一步展示了TKV的效用并揭示了其与肾功能关系的局限;未来可采用适应性方法、主方案(平台和伞式设计)及目标试验模拟等创新设计以提高效率、减少样本量并加速疗法开发。
要点
- ADPKD进展缓慢,传统肾功能终点试验需大量时间与资源。
- TKV已被验证为预后生物标志物和合理可能替代终点,可减少对功能终点的依赖。
- 适应性设计、主方案和目标试验模拟等创新方法有望提高ADPKD试验效率。
核心结论
- ADPKD临床试验设计已从肾功能终点转向以TKV为合理可能替代终点,并可能进一步采用适应性方法、主方案和目标试验模拟等创新设计以提高效率。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- CRISP研究验证了TKV作为预后生物标志物,使试验设计得以摆脱功能终点。
- HALT-PKD和TEMPO 3:4等干预试验进一步证明了TKV的效用,同时揭示了肾体积与功能关系的潜在局限性。
- 适应性方法、主方案(平台和伞式设计)及目标试验模拟可能降低ADPKD试验成本、增强统计效能并加速疗法开发。
临床怎么用
- 在ADPKD临床试验中可考虑采用TKV作为替代终点以缩短试验周期和降低资源投入。
- 可探索适应性设计、主方案和目标试验模拟等创新方法以提高试验效率和统计效能。
局限性
- 肾体积与肾功能之间的关系存在潜在局限性,需在试验设计中加以考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by continuous growth in the size and number of kidney cysts during decades of relatively preserved renal function. Because of this slow progression, traditional clinical trial design, focused on kidney functional outcomes such as change in estimated glomerular filtration rate (eGFR) or time to kidney failure, requires significant investment of time and resources. This review examines the evolution of trial design to overcome these barriers, highlighting the pivotal shift to using total kidney volume (TKV) as a reasonably likely surrogate end point. Foundational studies such as the Consortium for Radiologic Imaging Studies in Polycystic Kidney Disease (CRISP) validated TKV as a prognostic biomarker, enabling a move away from functional end points. Subsequent interventional trials (e.g., HALT-PKD, TEMPO 3:4) further demonstrated the utility of TKV while revealing potential limitations in the relationship between kidney volume and function. Building on these lessons, the field could move to more sophisticated designs to improve efficiency and limit study size. Innovative approaches including adaptive methods, master protocols (i.e., platform and umbrella designs), and target trial emulation may reduce costs, enhance statistical power, and accelerate the development of therapeutic options for ADPKD.
引用
- Roth JR, Dahl NK, Garimella PS, et al. Evolution of Clinical Trial Design in ADPKD. Kidney Int Rep. 2026. PMID: 41736773. doi:10.1016/j.ekir.2026.103786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。